Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer

Journal of the National Cancer Institute

Volumn 106, Issue 7, 2014, Pages

  Fuentes Mattei, Enrique ^d   Velazquez Torres, Guermarie ^a,b,d   Phan, Liem ^a,d   Zhang, Fanmao ^a,d   Chou, Ping Chieh ^a,b,d   Shin, Ji Hyun ^a,b,d   Choi, Hyun Ho ^a,b,d   Chen, Jiun Sheng ^d   Zhao, Ruiying ^d   Chen, Jian ^d   Gully, Chris ^a,c,d   Carlock, Colin ^a,b,d   Qi, Yuan ^d   Zhang, Ya ^d   Wu, Yun ^d   Esteva, Francisco J ^a,d   Luo, Yongde ^e   McKeehan, Wallace L ^e   Ensor, Joe ^d   Hortobagyi, Gabriel N ^d   Pusztai, Lajos ^d,f   Fraser Symmans, W ^d   Lee, Mong Hong ^a,b,c,d   Jim Yeung, Sai Ching ^a,d,e   more..

^a UNIVERSITY OF TEXAS   (United States)

^b Cancer Biology Graduate Program   (United States)

^c The Genes and Development Graduate Program   (United States)

^d Department of Molecular and Cellular Oncology ^*  (United States)

^e UNIVERSITY OF TEXAS   (United States)

^f YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PROTEIN KINASE B; TRANSCRIPTOME;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; EPITHELIAL MESENCHYMAL TRANSITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INSULIN TOLERANCE TEST; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; OBESITY; ONCOGENE; ORAL GLUCOSE TOLERANCE TEST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; TRANSCRIPTOMICS; TUMOR GROWTH;

ADIPOCYTES; ADIPOKINES; AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; METFORMIN; MICE; MICE, TRANSGENIC; MIDDLE AGED; OBESITY; POSTMENOPAUSE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES; TRANSCRIPTOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905261317     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju158     Document Type: Article

References (38)

1. Renehan AG, Tyson M, Egger M, et al. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371(9612):569-578.
2. La Vecchia C, Negri E, Franceschi S, et al. Body mass index and post-menopausal breast cancer: An age-specific analysis. Br J Cancer. 1997;75(3):441-444.
3. Petrelli JM, Calle EE, Rodriguez C, et al. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control. 2002;13(4):325-332.
4. Carmichael AR. Obesity as a risk factor for development and poor prognosis of breast cancer. BJOG. 2006;113(10):1160-1166.
5. Renehan AG, Soerjomataram I, Tyson M, et al. Incident cancer burden attributable to excess body mass index in 30 European countries. Int J Cancer. 2010;126(3):692-702.
6. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. Breast Cancer Res Treat. 2010;123(3):627-635.
7. Grossmann ME, Ray A, Nkhata KJ, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev. 2010;29(4):641-653.
8. Taubes G. Unraveling the obesity-cancer connection. Science. 2012;335(6064):28-32.
9. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.
10. Hatzis C, Pusztai L, Valero V, et al. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011;305(18):1873-1881.
11. Symmans WF, Ayers M, Clark EA, et al. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma. Cancer. 2003;97(12):2960-2971.
12. Symmans WF, Peintinger F, Hatzis C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25(28):4414-4422.
13. Bassukas ID, Vester G, Maurer-Schultze B. Cell kinetic studies of endothelial cells in the adenocarcinoma EO 771 and the effect of cyclophosphamide. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990;59(4):251-256.
14. Pan J, Chen C, Jin Y, et al. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012;11(12):2314-2326.
15. Zhao R, Fuentes-Mattei E, Velazquez-Torres G, et al. Exenatide improves glucocorticoid-induced glucose intolerance in mice. Diabetes Metab Syndr Obes. 2011;4:61-65.
16. Fuentes-Mattei E, Rivera E, Gioda A, et al. Use of human bronchial epithelial cells (BEAS-2B) to study immunological markers resulting from exposure to PM(2.5) organic extract from Puerto Rico. Toxicol Appl Pharmacol. 2010;243(3):381-389.
17. Krzywinski M, Schein J, Birol I, et al. Circos: An information aesthetic for comparative genomics. Genome Res. 2009;19(9):1639-1645.
18. Zhao R, Yeung SC, Chen J, et al. Subunit 6 of the COP9 signalosome promotes tumorigenesis in mice through stabilization of MDM2 and is upregulated in human cancers. J Clin Invest. 2011;121(3):851-865.
19. Gully CP, Velazquez-Torres G, Shin JH, et al. Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A. 2012;109(24):E1513-E1522.
20. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
21. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94(446):496-509.
22. Song R, Peng W, Zhang Y, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 2013;494(7437):375-379.
23. Yi JS, Park JS, Ham YM, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nat Commun. 2013;4:2354.
24. Yang WL, Wang J, Chan CH, et al. The E3 ligase TRAF6 regulates Akt ubiquitination and activation. Science. 2009;325(5944):1134-1138.
25. Krzywinski M, Birol I, Jones SJ, et al. Hive plots-rational approach to visualizing networks. Brief Bioinform. 2012;13(5):627-644.
26. Zheng Q, Dunlap SM, Zhu J, et al. Leptin deficiency suppresses MMTVWnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. Endocr Relat Cancer. 2011;18(4):491-503.
27. Ribeiro AM, Andrade S, Pinho F, et al. Prostate cancer cell proliferation and angiogenesis in different obese mice models. Int J Exp Pathol. 2010;91(4):374-386.
28. Dogan S, Hu X, Zhang Y, et al. Effects of high-fat diet and/or body weight on mammary tumor leptin and apoptosis signaling pathways in MMTVTGF-alpha mice. Breast Cancer Res. 2007;9(6):R91.
29. Nogueira LM, Dunlap SM, Ford NA, et al. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer. 2012;19(1):57-68.
30. Chen CT, Du Y, Yamaguchi H, et al. Targeting the IKKbeta/mTOR/ VEGF signaling pathway as a potential therapeutic strategy for obesityrelated breast cancer. Mol Cancer Ther. 2012;11(10):2212-2221.
31. Asterholm IW, Scherer PE. Metabolic jet lag when the fat clock is out of sync. Nat Med. 2012;18(12):1738-1740.
32. Paschos GK, Ibrahim S, Song WL, et al. Obesity in mice with adipocyte-specific deletion of clock component Arntl. Nat Med. 2012;18(12):1768-1777.
33. Johnson AM, Olefsky JM. The origins and drivers of insulin resistance. Cell. 2013;152(4):673-684.
34. Tao Y, Pinzi V, Bourhis J, et al. Mechanisms of disease: signaling of the insulin-like growth factor 1 receptor pathway-therapeutic perspectives in cancer. Nat Clin Pract Oncol. 2007;4(10):591-602.
35. Schrohl AS, Holten-Andersen MN, Peters HA, et al. Tumor tissue levels of tissue inhibitor of metalloproteinase-1 as a prognostic marker in primary breast cancer. Clin Cancer Res. 2004;10(7):2289-2298.
36. Lee JH, Choi JW, Kim YS. Serum TIMP-1 predicts survival outcomes of invasive breast carcinoma patients: A meta-analysis. Arch Med Res. 2011;42(6):463-468.
37. Fu ZY, Lv JH, Ma CY, et al. Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-small ka, CyrillicB pathway. Biomed Pharmacother. 2011;65(3):163-167.
38. Esteva FJ, Moulder SL, Gonzalez-Angulo AM, et al. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71(1):63-72